MacroGenics is a biopharmaceutical company focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. Co.'s MARGENZA (margetuximab-cmkb) is a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In addition, Co. has a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, that have been created primarily using its proprietary, antibody-based technology platforms. The MGNX stock yearly return is shown above.
The yearly return on the MGNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MGNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|